MarketCapExport financials
Danaher Corporation (DHR)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Danaher Corporation Income Statement 2025-2006 | DHR
Brief overview of financial results at Danaher Corporation
The figures are compared over a five-year interval. Danaher Corporation reported revenue of 22.3 billion dollars in 2020 and 24.6 billion dollars by 2025. Overall revenue changed by +10.2%, equal to an annualized rate of about 2%. The scale of the core business was largely unchanged.
The five-year change in gross profit reached +16.4%: from 12.5 billion dollars to 14.5 billion dollars. Revenue outpaced cost of revenue, allowing more sales to flow into gross profit. At the margin level, the figure shifted from 56% to 59.1%. The margin shift points to a more favorable sales-and-cost structure.
Over the period, EBITDA shifted from 6 billion dollars to 5.4 billion dollars, a change of −9.4%. EBITDA lagged revenue, showing weaker operating momentum. Comparing the endpoints gives EBITDA margins of 27% and 22.1%. A lower EBITDA share weakens the quality of the result.
Net profit was 3.6 billion dollars at the start and 3.6 billion dollars at the end. The final result remained comparatively stable.
Over the period, capitalization shifted from 155 billion dollars to 150 billion dollars (−3.2%). Investor perception of value changed only slightly.
Overall conclusion
The results present an uneven picture without one dominant signal. The positive side is supported by stable net income and improving gross profitability. Caution is warranted because of pressure on operating profitability and a softer top-line trend. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement Danaher Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
150 B | 152 B | 183 B | 181 B | 196 B | 155 B | 121 B | 76.4 B | 70.7 B | 55.5 B | 45.9 B | 43.9 B | 39.7 B | 31.5 B | 26.9 B | 17.3 B | 13.6 B | 16.7 B | 7.68 B | - |
Shares |
713 M | 731 M | 736 M | 725 M | 715 M | 706 M | 715 M | 701 M | 696 M | 691 M | 698 M | 702 M | 696 M | 693 M | 676 M | 653 M | 642 M | 639 M | 311 M | - |
Historical Prices |
210 | 208 | 249 | 250 | 274 | 219 | 143 | 125 | 95.9 | 83.3 | 44.7 | 43.3 | 37.8 | 30.4 | 26 | 26.5 | 21.2 | 26.1 | 24.7 | 21.8 |
Net Income |
3.61 B | 3.9 B | 4.76 B | 7.21 B | 6.43 B | 3.65 B | 3.01 B | 2.65 B | 2.49 B | 2.55 B | 3.36 B | 2.6 B | 2.7 B | 2.39 B | 2.17 B | 1.79 B | 1.15 B | 1.32 B | 1.37 B | - |
Revenue |
24.6 B | 23.9 B | 23.9 B | 26.6 B | 24.8 B | 22.3 B | 17.9 B | 19.9 B | 18.3 B | 16.9 B | 20.6 B | 19.9 B | 19.1 B | 18.3 B | 16.1 B | - | - | - | - | - |
Cost of Revenue |
10 B | 9.67 B | 9.86 B | 10.5 B | 9.56 B | 9.81 B | 7.93 B | 7.54 B | 6.95 B | 7.55 B | 6.66 B | 6.02 B | 8.94 B | 8.63 B | 7.91 B | 6.15 B | 5.45 B | 6.48 B | 5.99 B | - |
Gross Profit |
14.5 B | 14.2 B | 14 B | 16.2 B | 15.2 B | 12.5 B | 9.98 B | 11.1 B | 10.2 B | 9.33 B | 10.8 B | 10.4 B | 9.96 B | 9.41 B | 8.18 B | 6.4 B | 5.07 B | 5.79 B | - | - |
Operating Income |
4.69 B | 4.86 B | 5.2 B | 7.54 B | 6.38 B | 4.23 B | 3.27 B | 3.06 B | 2.57 B | 2.74 B | 2.16 B | 2.04 B | 3.12 B | 2.98 B | 2.62 B | 2.05 B | 1.44 B | 1.79 B | 1.74 B | - |
Interest Expense |
-222 M | -56 M | -175 M | -227 M | 231 M | 275 M | 108 M | 137 M | 140 M | 184 M | 140 M | 94.7 M | 141 M | 153 M | 142 M | 117 M | 119 M | 126 M | 110 M | - |
EBITDA |
5.44 B | 5.58 B | 5.88 B | 8.23 B | 8.44 B | 6.01 B | 4.46 B | 4.71 B | 4.26 B | 3.88 B | 4.52 B | 4.37 B | 4.17 B | 3.94 B | 3.19 B | 2.44 B | 1.77 B | 2.12 B | 1.91 B | - |
Operating Expenses |
- | - | - | - | - | - | 6.71 B | 7.7 B | 7.17 B | 6.58 B | 7.29 B | 7.01 B | 6.68 B | 6.32 B | 5.63 B | - | - | - | - | - |
General and Administrative Expenses |
8.24 B | 7.76 B | 7.33 B | 7.12 B | 6.82 B | 6.9 B | 5.59 B | 6.47 B | 6.04 B | 5.61 B | 6.05 B | 5.7 B | 5.43 B | 5.18 B | 4.61 B | 3.6 B | 3.12 B | 3.3 B | 2.71 B | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Danaher Corporation
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q4 | 2009-Q3 | 2009-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
711 M | 716 M | 716 M | 2.7 M | 723 M | 738 M | 741 M | 719 M | 739 M | 737 M | 741 M | -9.2 M | 728 M | 727 M | 716 M | - | - | 727 M | 716 M | 715 M | 715 M | 714 M | 713 M | 711 M | 711 M | 705 M | 697 M | 696 M | 719 M | 718 M | 708 M | 702 M | 701 M | 700 M | 699 M | 697 M | 696 M | 695 M | 694 M | 692 M | 692 M | 691 M | 689 M | 687 M | 688 M | 710 M | 707 M | 704 M | 703 M | 701 M | 700 M | 698 M | 698 M | 695 M | 692 M | 688 M | 695 M | 696 M | 692 M | 688 M | 687 M | 667 M | 662 M | 1.68 M | 642 M | 640 M | 319 M | -8.08 M | 320 M | 319 M |
Net Income |
908 M | 555 M | 954 M | 1.93 B | 818 M | 907 M | 1.09 B | - | 1.13 B | 1.11 B | 1.09 B | 1.68 B | 1.55 B | 1.66 B | 1.68 B | - | - | 1.68 B | 1.72 B | - | 1.16 B | 1.78 B | 1.7 B | - | 883 M | 927 M | 595 M | 1.26 B | 668 M | 731 M | 334 M | 747 M | 664 M | 674 M | 567 M | 857 M | 572 M | 557 M | 506 M | 747 M | 392 M | 657 M | 758 M | 689 M | 1.4 B | 696 M | 570 M | 662 M | 681 M | 676 M | 580 M | 789 M | 597 M | 617 M | 692 M | 630 M | 549 M | 600 M | 613 M | 571 M | 523 M | 649 M | 429 M | 238 M | 351 M | 296 M | 238 M | 358 M | 372 M | 363 M |
Revenue |
6.05 B | 5.94 B | 5.74 B | 6.55 B | 5.8 B | 5.74 B | 5.8 B | - | 5.62 B | 5.91 B | 5.8 B | 6.53 B | 7.66 B | 7.75 B | 7.69 B | - | - | 7.75 B | 7.69 B | - | 7.23 B | 7.22 B | 6.86 B | - | 5.88 B | 5.3 B | 4.34 B | 4.87 B | 4.38 B | 4.44 B | 4.22 B | 5.36 B | 4.85 B | 4.98 B | 4.7 B | 5.09 B | 4.53 B | 4.51 B | 4.21 B | 4.58 B | 4.13 B | 4.24 B | 3.92 B | 4.32 B | 3.51 B | 4.96 B | 4.69 B | 5.22 B | 4.71 B | 4.96 B | 4.66 B | 5.04 B | 4.67 B | 4.74 B | 4.44 B | 4.98 B | 4.42 B | 4.55 B | 4.32 B | 4.72 B | 4.45 B | 3.64 B | 3.29 B | - | - | - | - | - | - | - |
Cost of Revenue |
2.53 B | 2.41 B | 2.23 B | 2.84 B | 2.4 B | 2.32 B | 2.31 B | - | 2.35 B | 2.59 B | 2.31 B | 471 M | 3.08 B | 3.03 B | 2.98 B | - | - | 3.03 B | 2.98 B | - | 2.87 B | 2.82 B | 2.6 B | - | 2.66 B | 2.44 B | 1.9 B | - | 1.94 B | 1.96 B | 1.87 B | - | 2.16 B | 2.16 B | 2.05 B | - | 1.99 B | 2.03 B | 1.87 B | - | 1.85 B | 1.86 B | 1.76 B | - | 1.62 B | 2.32 B | 2.23 B | - | 2.25 B | 2.34 B | 2.21 B | - | 2.24 B | 2.24 B | 2.12 B | - | 2.14 B | 2.2 B | 2.08 B | - | 2.26 B | 1.72 B | 1.54 B | 2.55 B | 1.43 B | 1.41 B | 1.37 B | 953 M | 1.7 B | 1.72 B |
Gross Profit |
3.52 B | 3.52 B | 3.51 B | 3.72 B | 3.4 B | 3.43 B | 3.49 B | - | 3.28 B | 3.32 B | 3.49 B | 4.06 B | 4.58 B | 4.72 B | 4.7 B | - | - | 4.72 B | 4.7 B | - | 4.36 B | 4.4 B | 4.25 B | - | 3.23 B | 2.85 B | 2.44 B | 2.7 B | 2.44 B | 2.48 B | 2.35 B | 2.53 B | 2.31 B | 2.39 B | 2.27 B | 2.84 B | 2.54 B | 2.48 B | 2.33 B | 2.5 B | 2.29 B | 2.38 B | 2.17 B | 2.26 B | 1.89 B | 1.88 B | 1.74 B | 2.66 B | 2.45 B | 2.49 B | 2.29 B | 2.54 B | 2.29 B | 2.35 B | 2.17 B | 2.55 B | 2.28 B | 2.36 B | 2.24 B | 2.33 B | 2.18 B | 1.92 B | 1.75 B | 1.26 B | 1.32 B | 1.26 B | - | - | - | - |
Operating Income |
1.15 B | 760 M | 1.27 B | 1.76 B | 958 M | 1.17 B | 1.31 B | - | 1.18 B | 1.16 B | 1.31 B | 1.93 B | 2.02 B | 2.2 B | 2.17 B | - | - | 2.2 B | 2.17 B | - | 1.31 B | 2 B | 2 B | - | 1.09 B | 844 M | 698 M | 962 M | 776 M | 812 M | 720 M | 863 M | 745 M | 759 M | 688 M | 938 M | 759 M | 677 M | 617 M | 729 M | 699 M | 710 M | 613 M | 652 M | 480 M | 583 M | 448 M | 867 M | 866 M | 876 M | 738 M | 855 M | 784 M | 805 M | 677 M | 863 M | 756 M | 811 M | 735 M | 779 M | 643 M | 610 M | 585 M | 340 M | 465 M | 344 M | 340 M | 295 M | 522 M | 510 M |
Interest Expense |
-14 M | -42 M | -79 M | -182 M | 102 M | -59 M | -36 M | - | -47 M | -15 M | -36 M | 608 M | -51 M | -87 M | -20 M | - | - | 51 M | 54 M | - | 62 M | 62 M | 58 M | - | 78 M | 78 M | 47 M | - | 24 M | 19.7 M | 20.5 M | - | 41.3 M | 43.2 M | 39.1 M | - | 39.9 M | 40.7 M | 40.3 M | - | 43.7 M | 55.5 M | 52.9 M | - | 39.1 M | 29 M | 29.3 M | - | 29.6 M | 33.2 M | 32.5 M | - | 35 M | 39.4 M | 39.2 M | - | 39.4 M | 37.9 M | 39.4 M | - | 42.4 M | 31.4 M | 30.4 M | 42.9 M | 31.8 M | 31.3 M | 24.1 M | 4.96 M | 30.2 M | 33.9 M |
EBITDA |
1.59 B | 1.19 B | 1.68 B | 2.03 B | 1.37 B | 1.57 B | 1.72 B | - | 1.55 B | 1.16 B | 1.49 B | 2.2 B | 2.38 B | 2.58 B | 2.56 B | - | - | 2.2 B | 2.35 B | - | 1.31 B | 2.34 B | 2.16 B | - | 1.55 B | 1.15 B | 839 M | 962 M | 1.2 B | 1.09 B | 858 M | 863 M | 1.19 B | 1.06 B | 836 M | 938 M | 1.19 B | 959 M | 756 M | 729 M | 1.1 B | 972 M | 742 M | 652 M | 829 M | 856 M | 583 M | 867 M | 1.27 B | 1.15 B | 870 M | 855 M | 1.17 B | 1.06 B | 804 M | 863 M | 1.12 B | 1.06 B | 856 M | 779 M | 873 M | 715 M | 633 M | 347 M | 511 M | 390 M | 386 M | 324 M | 569 M | 510 M |
General and Administrative Expenses |
1.99 B | 2.36 B | 1.86 B | 1.59 B | 2.06 B | 1.87 B | 1.81 B | - | 1.73 B | 1.79 B | 1.81 B | 491 M | 2.15 B | 2.08 B | 2.09 B | - | - | 2.08 B | 2.09 B | - | 2.06 B | 1.97 B | 1.88 B | - | 1.8 B | 1.68 B | 1.46 B | - | 1.38 B | 1.39 B | 1.37 B | - | 1.56 B | 1.64 B | 1.6 B | - | 1.5 B | 1.52 B | 1.45 B | - | 1.35 B | 1.43 B | 1.33 B | - | 1.2 B | 1.4 B | 1.41 B | - | 1.3 B | 1.39 B | 1.35 B | - | 1.3 B | 1.34 B | 1.3 B | - | 1.25 B | 1.28 B | 1.24 B | - | 1.27 B | 1.09 B | 963 M | 1.05 B | 782 M | 760 M | 757 M | 228 M | 806 M | 860 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Danaher Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K |  USA |
 |
Waters Corporation
WAT
|
$ 476.29 | -0.09 % | $ 28.4 B | USA |
 |
Exagen
XGN
|
$ 5.26 | -25.92 % | $ 113 M | USA |
 |
Celcuity
CELC
|
$ 67.13 | -4.11 % | $ 3.14 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 370.89 | -0.25 % | $ 30.9 B | USA |
 |
Lantheus Holdings
LNTH
|
$ 101.65 | 0.63 % | $ 6.86 B | USA |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Medpace Holdings
MEDP
|
$ 664.97 | -1.18 % | $ 19.2 B | USA |
 |
Charles River Laboratories International
CRL
|
$ 346.21 | -2.02 % | $ 17.2 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 750.2 | -0.69 % | $ 36.1 B |  Schweiz |
 |
Koninklijke Philips N.V.
PHG
|
$ 30.39 | -1.32 % | $ 28.8 B |  Niderland |
 |
RadNet
RDNT
|
$ 77.91 | -0.6 % | $ 5.86 B | USA |
 |
Senseonics Holdings
SENS
|
$ 10.05 | 2.55 % | $ 419 M | USA |
 |
Neuronetics
STIM
|
$ 2.01 | -7.8 % | $ 133 M | USA |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
Thermo Fisher Scientific
TMO
|
$ 719.09 | -0.35 % | $ 271 B | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Guardant Health
GH
|
$ 155.43 | -2.12 % | $ 19.5 B | USA |
 |
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
$ 10.63 | -8.68 % | $ 361 M |  Israel |
 |
VolitionRx Limited
VNRX
|
$ 0.19 | -6.2 % | $ 23.9 M |  Singapore |
 |
Natera
NTRA
|
$ 311.81 | -1.92 % | $ 42.6 B | USA |
 |
IQVIA Holdings
IQV
|
$ 275.46 | -1.21 % | $ 47.4 B | USA |
 |
Agilent Technologies
A
|
$ 178.84 | -0.74 % | $ 50.8 B | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | Schweiz |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
- | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | Israel |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
 |
DexCom
DXCM
|
$ 79.92 | -1.42 % | $ 31.2 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
$ 258.38 | -0.5 % | $ 28.7 B | USA |
 |
Castle Biosciences
CSTL
|
$ 34.41 | 0.07 % | $ 997 M | USA |
 |
IDEXX Laboratories
IDXX
|
$ 696.77 | -1.4 % | $ 56 B | USA |
 |
Illumina
ILMN
|
$ 214.84 | -2.69 % | $ 33.3 B | USA |
 |
Anixa Biosciences
ANIX
|
$ 3.05 | -3.48 % | $ 99 K | USA |
|
Biodesix
BDSX
|
$ 10.04 | -2.95 % | $ 75.8 M | USA |
 |
BioNano Genomics
BNGO
|
$ 1.25 | 7.66 % | $ 6.81 M | USA |
 |
Bioventus
BVS
|
$ 11.18 | 1.5 % | $ 745 M | USA |
 |
Fulgent Genetics
FLGT
|
$ 25.83 | -1.22 % | $ 795 M | USA |
 |
CareDx, Inc
CDNA
|
$ 80.78 | -4.31 % | $ 4.3 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
- | - | $ 562 M | Britain |
 |
Biomerica
BMRA
|
$ 1.48 | -4.52 % | $ 4.31 M | USA |